[1]
Nieuwlaat R, Prins MH, Le Heuzey JY, et al. Prognosis, disease progression, and treatment of atrial fibrillation patients during 1 year: follow-up of the Euro heart survey on atrial fibrillation. Eur Heart J 2008; 29(9): 1181-9.
[2]
Linz D, Elliott AD, Marwick TH, Sanders P. Biomarkers and new-onset atrial fibrillation to assess atrial cardiomyopathy. Int J Cardiol 2017; 248: 208-10.
[3]
Nichols GA, Reinier K, Chugh SS. Independent contribution of diabetes to increased prevalence and incidence of atrial fibrillation. Diabetes Care 2009; 32(10): 1851-6.
[4]
Skalidis EI, Hamilos MI, Karalis IK, Chlouverakis G, Kochiadakis GE, Vardas PE. Isolated atrial microvascular dysfunction in patients with lone recurrent atrial fibrillation. J Am Coll Cardiol 2008; 51(21): 2053-7.
[5]
Mihm MJ, Yu F, Carnes CA, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104(2): 174-80.
[6]
Smit MD, Maass AH, De Jong AM, et al. Role of inflammation in early atrial fibrillation recurrence. Europace 2012; 14(6): 810-7.
[7]
Weijs B, Pisters R, Haest RJ, et al. Patients originally diagnosed with idiopathic atrial fibrillation more often suffer from insidious coronary artery disease compared to healthy sinus rhythm controls. Heart Rhythm 2012; 9(12): 1923-9.
[8]
Andersson T, Magnuson A, Bryngelsson IL, et al. Gender-related differences in risk of cardiovascular morbidity and all-cause mortality in patients hospitalized with incident atrial fibrillation without concomitant diseases: a nationwide cohort study of 9519 patients. Int J Cardiol 2014; 177(1): 91-9.
[9]
van Zonneveld AJ, Rabelink TJ, Bijkerk R. MiRNA-coordinated networks as promising therapeutic targets for acute kidney injury. Am J Pathol 2017; 187(1): 20-4.
[10]
Creemers EE, Tijsen AJ, Pinto YM. Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease? Circ Res 2012; 110(3): 483-95.
[11]
Florijn BW, Bijkerk R, van der Veer EP, van Zonneveld AJ. Gender and cardiovascular disease: are sex-biased microRNA networks a driving force behind heart failure with preserved ejection fraction in women? Cardiovasc Res 2018; 114(2): 210-25.
[12]
Bijkerk R, Duijs JM, Khairoun M, et al. Circulating microRNAs associate with diabetic nephropathy and systemic microvascular damage and normalize after simultaneous pancreas-kidney transplantation. Am J Transplant 2015; 15(4): 1081-90.
[13]
Wei XJ, Han M, Yang FY, et al. Biological significance of mir-126 expression in atrial fibrillation and heart failure. Braz J Med Biol Res 2015; 48(11): 983-9.
[14]
McManus DD, Lin H, Tanriverdi K, et al. Relations between Circulating microRNAs and atrial fibrillation: data from the framingham offspring study. Heart Rhythm 2014; 11(4): 663-9.
[15]
Bijkerk R, Florijn BW, Khairoun M, et al. Acute rejection after kidney transplantation associates with circulating microRNAs and vascular injury. Transplant Direct 2017; 3(7): e174.
[16]
Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular munster (procam) study. Circulation 2002; 105(3): 310-5.
[17]
Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte M Jr, Detrano R. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15(4): 827-32.
[18]
Mestdagh P, Van Vlierberghe P, De Weer A, et al. A novel and universal method for microRNA Rt-Qpcr data normalization. Genome Biol 2009; 10(6): R64.
[19]
Khairoun M, de Koning EJ, van den Berg BM, et al. Microvascular damage in type 1 diabetic patients is reversed in the first year after simultaneous pancreas-kidney transplantation. Am J Transplant 2013; 13(5): 1272-81.
[20]
Catanzaro G, Besharat ZM, Chiacchiarini M, et al. Circulating microRNAs in elderly type 2 diabetic patients. Int J Endocrinol 2018; 2018: 6872635.
[21]
de Boer HC, van Solingen C, Prins J, et al. Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. Eur Heart J 2013; 34(44): 3451-7.
[22]
Liu Z, Zhou C, Liu Y, et al. The expression levels of plasma micoRNAs in atrial fibrillation patients. PLoS One 2012; 7(9): e44906.
[23]
Goren Y, Meiri E, Hogan C, et al. Relation of reduced expression of miR-150 in platelets to atrial fibrillation in patients with chronic systolic heart failure. Am J Cardiol 2014; 113(6): 976-81.
[24]
McManus DD, Tanriverdi K, Lin H, et al. Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation (the mirhythm study). Heart Rhythm 2015; 12(1): 3-10.
[25]
Karakas M, Schulte C, Appelbaum S, et al. Circulating microRNAs strongly predict cardiovascular death in patients with coronary artery disease-results from the large atherogene study. Eur Heart J 2017; 38(7): 516-23.
[26]
Tao H, Zhang M, Yang JJ, Shi KH. MicroRNA-21 via dysregulation of ww domain-containing protein 1 regulate atrial fibrosis in atrial fibrillation. Heart Lung Circ 2018; 27(1): 104-13.
[27]
Haque R, Hur EH, Farrell AN, Iuvone PM, Howell JC. Microrna-152 represses VEGF and tgfbeta1 expressions through post-transcriptional inhibition of (pro)renin receptor in human retinal endothelial cells. Mol Vis 2015; 21: 224-35.
[28]
Hartmann P, Zhou Z, Natarelli L, et al. endothelial dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of Klf4. Nat Commun 2016; 7: 10521.
[29]
Kumarswamy R, Volkmann I, Beermann J, et al. Vascular importance of the miR-212/132 cluster. Eur Heart J 2014; 35(45): 3224-31.
[30]
Bijkerk R, van Solingen C, de Boer HC, et al. Hematopoietic microRNA-126 protects against renal ischemia/reperfusion injury by promoting vascular integrity. J Am Soc Nephrol 2014; 25(8): 1710-22.
[31]
Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007; 9(6): 654-9.
[32]
Vickers KC, Palmisano BT, Shoucri BM, Shamburek RD, Remaley AT. microRNAs are transported in plasma and delivered to recipient cells by high-density lipoproteins. Nat Cell Biol 2011; 13(4): 423-33.
[33]
Arroyo JD, Chevillet JR, Kroh EM, et al. Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma. Proc Natl Acad Sci USA 2011; 108(12): 5003-8.
[34]
Mocharla P, Briand S, Giannotti G, et al. Angiomir-126 expression and secretion from circulating CD34(+) and Cd14(+) Pbmcs: role for proangiogenic effects and alterations in type 2 diabetics. Blood 2013; 121(1): 226-36.
[35]
Tabet F, Vickers KC, Cuesta Torres LF, et al. HDL-Transferred microRNA-223 regulates Icam-1 expression in endothelial cells. Nat Commun 2014; 5: 3292.
[36]
Florijn BW, Bijkerk R, van der Veer E, van Zonneveld AJ. Gender and cardiovascular disease: are sex-biased miRNA networks a driving force behind heart failure with preserved ejection fraction in women? Cardiovasc Res 2018; 114(2): 210-25.
[37]
Cui C, Yang W, Shi J, et al. Identification and analysis of human sex-biased microRNAs. Genomics Proteomics Bioinformatics 2018; 16(3): 200-11.
[38]
Li P, Wei J, Li X, et al. 17beta-estradiol enhances vascular endothelial ets-1/miR-126-3p expression: the possible mechanism for attenuation of atherosclerosis. J Clin Endocrinol Metab 2017; 102(2): 594-603.
[39]
Ameling S, Kacprowski T, Chilukoti RK. al. Associations of circulating plasma microRNAs with age, body mass index and sex in a population-based study. BMC Med Genomics 2015; 8: 61.
[40]
Wang M, Sun J, Xu B, et al. Functional characterization of microRNA-27a-3p expression in human polycystic ovary syndrome. Endocrinology 2018; 159(1): 297-309.
[41]
Mackenzie NC, Staines KA, Zhu D, Genever P, Macrae VE. MiRNA-221 and miRNA-222 synergistically function to promote vascular calcification. Cell Biochem Funct 2014; 32(2): 209-16.
[42]
Gui B, Hsieh CL, Kantoff PW, Kibel AS, Jia L. Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer. PLoS One 2017; 12(9): e0184166.
[43]
Liu W, Ling S, Sun W, et al. Circulating microRNAs correlated with the level of coronary artery calcification in symptomatic patients. Sci Rep 2015; 5: 16099.
[44]
Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide retrospective cohort study. BMJ 2012; 344: e3522.
[45]
Weijs B, Blaauw Y, Rennenberg RJ, et al. Patients using vitamin K antagonists show increased levels of coronary calcification: an observational study in low-risk atrial fibrillation patients. Eur Heart J 2011; 32(20): 2555-62.
27
2